The paucity of recurrent mutations has hampered efforts to understand the pathogenesis of 29 neuroblastoma. Through analysis of RNA-sequenced neuroblastoma, we identified >900 primarily 30 intrachromosomal fusion transcripts generated by genes in close proximity. Fusions were enriched 31 in chromosomal regions gained or lost in neuroblastoma and included well-known neuroblastoma 32 oncogenes. The majority of fusions contained canonical splicing sites and a subset exhibited 33 increased sensitivity to spliceosome inhibition. As a proof-of-principle that a gene product with 34 altered properties can be produced by these fusions, we characterized the ZNF451-BAG2 fusion 35 which generates a truncated BAG2-protein capable of inhibiting retinoic acid-induced 36 differentiation. Our findings elucidate a mechanism through which altered gene products, relevant 37 for neuroblastoma pathogenesis and representing possible novel drug targets, can be generated. 38 39 413
Introduction 40
Despite intense sequencing efforts few recurrently mutated genes have been identified in 41 neuroblastoma (1, 2), resulting in a deficiency of drug targets. Instead, high-risk neuroblastoma is 42 characterized by large-scale chromosomal rearrangements such as chromothripsis and loss or gain of 43 chromosomal regions (e.g. loss of 1p36 and 11q or gain of 17q and 2p) with or without MYCN 44 amplification (1, 3) . Certain other types of tumors harbor and are driven by fusion proteins generated 45 by chromosomal translocations (e.g. BCR-ABL in chronic myelogenous leukemia) (4). An additional 46 mode, through which fusion transcripts can be generated, is represented by cis-splicing of adjacent 47 genes (5, 6) . Besides a fusion resulting from small interstitial genomic deletions at 11q generating 48 either a MLL-FOXR1 or a PAFAH1B2-FOXR2 fusion (7) no intra-chromosomal chimeric transcripts have 49 been described in neuroblastoma. However, they have been shown to be present in different tumor 50 types as well as in non-transformed tissues and be promoted by different types of cellular stress such 51 as infections or mutations (8) (9) (10) (11) (12) . In order to explore whether neuroblastoma tumors harbor previously 52 undetected gene fusions, we analyzed a cohort of 172 sequenced neuroblastoma tumors. We 53 identified an abundance of fusion transcripts, of which a significant proportion exhibited a distinct 54 genomic distribution according to tumor risk. Identified fusions were predominantly generated by 55 genes in close proximity and flanked by canonical splicing donors and acceptors. This pattern was 56 distinct to fusions unique for neuroblastoma, whereas fusions we identified in normal adrenal gland 57 or in other tumors did not exhibit such a pattern. Furthermore, a subset of identified NB specific fusions 58 was hypersensitive to pharmacologic spliceosome inhibition in comparison to their wild type cognates. 59
High expression levels of spliceosome factors were strongly associated with high-risk disease and 60 spliceosome inhibition also promoted apoptosis in neuroblastoma cells. As a proof of principle, that 61 fusions can generate novel gene products with alternative properties, we cloned and characterized the 62 ZNF451-BAG2 fusion. The generated protein exhibited distinct protein-protein binding properties 63 compared to wild-type BAG2 and impeded retinoic acid induced differentiation. This reveals how a 64 fusion gene product can influence neuroblastoma response to a drug commonly used in the treatment 65 of high-risk patients (13) . 66
Results 67
Fusion transcripts are a common feature of neuroblastoma 68
To reveal novel gene fusions in neuroblastoma we analyzed a data set (National Cancer Institute 69 TARGET, dbGap Study Accession: phs000218.v16.p6) comprising 172 paired-end RNA sequenced 70 neuroblastoma tumors (referred to as "NB172"), out of which 139 were diagnosed as high-risk, 19 as 71
intermediate-risk and 14 as low-risk according to the Children's Oncology Groups staging (COG), 72
( Supplementary Table 1 ). We applied the fusion detection tool FusionCatcher (14) and identified 73 chimeric transcripts in 163 out of 172 cases with an average of 31 distinct fusion transcripts per tumor 74 (Supplementary Table 2 ). Short homologous sequences (SHS) have been suggested to serve as 75 templates for reverse transcriptase dependent false positive chimeras/fusions (15). In order to avoid 76 potential false positive fusions, we removed any fusion that contained genes with SHSs of five or more 77 nucleotides, which reduced the number of identified fusions from 1073 to 924. The structural 78 consequences of the fusions ranged from truncated proteins through bona fide fusion proteins to 79 deletion of genes. The majority of fusions (786/924) revealed by our analysis were intra-chromosomal 80 fusion transcripts (Supplementary Table 2 -3) many of which consisted of adjacent genes. Importantly, 81 114 fusions occurred at a frequency of 5% or more (Top 25 in Fig. 1a, all >10% in Fig. 1b and full list in 82 Supplementary Table 3 ) and all of these were intrachromosomal. There was a significant enrichment 83 of fusion junctions at chromosomes 17 and 22 ( Supplementary Fig. 1a ). Furthermore, there was a 84 significant enrichment of fusions that occurred in >10% of tumors at the same chromosomes ( Fig. 1b) . 85
Gain of 17q is the most frequently occurring genomic alteration in high-risk neuroblastoma and a 86 marker for adverse clinical outcome (3), whereas 22q alterations have been reported to be involved in 87 the transition to metastatic and more aggressive neuroblastoma (16). We analyzed the fusion 88 transcripts occurring exclusively in low/intermediate-risk and exclusively in high-risk tumors as well as 89 fusion transcripts common to low/intermediate-risk and high-risk levels ( Supplementary Table 4 -5) . 90
Chimeric transcripts unique to low/intermediate-risk tumors exhibited significant enrichment at 91 several chromosomal arms including 11q, a region commonly lost in high-risk neuroblastoma (Fig. 1c) . 92
In contrast, both common and high-risk unique fusion transcripts were enriched at 17q and 22q but 93 not at 11q ( Fig. 1c) , with a pronounced increase in frequency of 17q fusion transcripts in high-risk 94 tumors ( Fig. 1c ). Thus, with increased risk the frequency of 17q located fusion junctions also increases 95 and was more than seven times higher than the average fusion rate per chromosomal arm. Several 96 fusion transcripts encompassed factors involved in neuroblastoma pathogenesis, including ARID1B, 97 CASZ1, HDAC8, LMO1, MYCN, BRCA1, TERT and PDE6G ( Supplementary Table 6 ). Notably, tumors 98 harboring fusion transcripts of well-known neuroblastoma oncogenes (e.g. MYCN and LMO1) also 99 exhibited high expression levels of their wild-type cognates ( Fig. 1 d-e ). The high-risk susceptibility 100 locus in LMO1 is significantly associated with MYCN-non amplified high-risk neuroblastoma but not 101 with MYCN-amplified high-risk neuroblastoma (17), interestingly the LMO1-RIC3 fusion 102 ( Supplementary Fig. 1b ) was exclusively detected in MYCN-non amplified high-risk neuroblastoma 103
( Supplementary Table 6 ). The BRCA1-VAT1 fusion was also only detected in MYCN-non amplified high-104 risk cases; previously it has been shown that copy number amplification of BRCA1 in NB is restricted to 105 cases lacking MYCN-amplification (18) ( Supplementary Table 6 ). 106 107
Validation of fusion transcripts specific for neuroblastoma 108
To corroborate the fusion transcripts observed in the NB172 dataset in an independent cohort, we 109 performed paired-end RNA-sequencing in an additional cohort containing 14 neuroblastoma patient 110 samples, together with eight neuroblastoma cell lines, Supplementary table 7, 111 Materials and Methods). We identified 139 fusions, of which 82 (~59%) were present in the NB172 112 dataset ( Fig. 2a and Supplementary Table 8 ). To investigate whether the identified fusions were 113 neuroblastoma specific, we analyzed a cohort of 161 sequenced tissue samples from human normal 114 adrenal glands (19) . Out of 342 detected fusions in the adrenal gland cohort, only 23 (~6.7%) were 115 present in the NB172 dataset and only 4 (~1.2%) of these were present in the NB-v cohort ( Fig. 2a and 116 Supplementary Table 9 ). This enrichment of common fusion transcripts in the neuroblastoma cohorts 117 vs. the adrenal gland dataset was highly significant (chi-square test with Yate's correction, p-118 value<0.0001). Fusion transcript associated genes unique to and shared by the two neuroblastoma 119 datasets were enriched at 17q and 2p, two chromosomal regions where gains are closely associated 120 with high-risk neuroblastoma (Fig. 2b ). Parametric analysis of gene set enrichment (PAGE) (20) 121 comparing high-risk grade 4 tumors with low-risk grade 4s tumors (according to the International 122 Neuroblastoma Staging System, INSS) in the R2 498-SEQC data base (21) showed that the NB172/NB-123 v common genes identified in Fig. 2a are enriched in the grade 4 high-risk tumors (Fig. 2c ). To further 124 investigate whether the identified fusions are distinct for neuroblastoma we analyzed a set of 65 125 sequenced rhabdoid tumors (National Cancer Institute TARGET, dbGap Study Accession: 126 phs000470.v17.p7) wherein 2055 unique fusion transcripts were detected. However, the overlap with 127 the fusions detected in NB172 dataset was limited to 44 transcripts (~2.1%) ( Fig. 2d ). In a cohort of 177 128 sequenced osteosarcoma tumors (National Cancer Institute TARGET, dbGap Study Accession: 129 phs000468.v17.p7; Fig. 2d ) we could detect 1650 unique fusion transcripts but there was no overlap 130 with the NB172 cohort ( Fig. 2d ). In contrast to fusions detected in neuroblastoma, the majority of 131 detected fusions in rhabdoid tumors and osteosarcoma were inter-chromosomal ( Supplementary Fig.  132 2a). Detected fusions that occur at higher frequencies than 5% are more abundant in neuroblastoma 133 (in 12.3% of tumors) than in rhabdoid tumor (5.7%) and osteosarcoma (0.4%) ( Supplementary Fig. 2b ). 134
In osteosarcoma there was a considerable number of tumors (~24.9%, 44/177) harboring fusions 135 predicting substantial deletion of the P53 tumor suppressor, disruption of the gene or a truncation at 136 the C-terminal ( Fig. 2e , Supplementary Table 10 ). Notably, TP53 is one of the most frequently altered 137 genes in osteosarcoma (22) . As a comparison we could not detect any fusions containing TP53 in the 138 neuroblastoma tumors (0/172) ( Fig. 2e) . 139
140
For further validation, we designed primers spanning the fusion junctions of selected chimeric 141 transcripts VPS45-PLEKHO1, METTL23-MFSD11, HDAC8-CITED1, ZNF451-BAG2, TRIM3-HPX and 142 PRR11-SMG8 ( Supplementary Table 11 ). We proceeded to perform RT-PCR in 10 neuroblastoma tumor 143 samples and in a panel consisting of cDNA from 14 untransformed human tissues. Our expression 144 analysis revealed that all selected candidates, except PRR11-SMG8, were expressed in a 145 neuroblastoma specific manner ( Fig. 2f ). For validation, PCR-products including four additional fusions, 146 TAF15-AC015849.2, FADS1-TMEM258, CHCHD10-VPREB3 and LMO1-RIC3, were excised, inserted into 147 the pCR-Blunt II-TOPO vector and subsequently sequenced. All the sequenced PCR-products exhibited 148 an identical sequence of nucleotides to that of the fusions identified by FusionCatcher ( Fig. 2f and 149 Supplementary Table 11 -12) . A previous report identified the VPS45-PLEKHO1 fusion in non-150 transformed tissue (12) One of the 25 most frequently occurring identified fusion transcripts encompassed the BCL2 associated 155 athanogene (BAG2) which encodes a co-chaperone, BAG2, involved in targeting misfolded proteins for 156 degradation through an ubiquitin independent pathway (23). BAG2 levels have previously been shown 157 to increase upon neuronal differentiation in neuroblastoma cells (24). In addition, BAG2 clears 158 phosphorylated TAU from neuronal microtubule (23), potentially promoting stabilization of axons, an 159 important feature of neuronal differentiation. We thus selected ZNF451-BAG2 to investigate if the 160 presence of a fusion transcript actually would generate a protein with altered functional properties. 161
162
To elucidate whether expression of the ZNF451-BAG2 fusion correlates with altered expression levels 163 of transcripts predicting clinical outcome we analyzed nine RNA-sequenced neuroblastoma tumors of 164 the NB-v cohort that had been validated by RT-PCR ( Fig. 2f ). Tumors harboring the ZNF451-BAG2 fusion 165 (3/9 tumors, A13, A14 and A15) had significantly elevated expression of 32 genes and 34 genes with 166 lower expression ( Fig. 3a ). To correlate these differentially expressed genes with clinical outcome we 167 utilized a cohort of 498 sequenced neuroblastoma tumors (498-SEQC) available in the R2 database 168 (21). The majority of genes with elevated expression was also enriched for in high-risk tumors whereas 169 the opposite was the case for genes with lower expression ( Fig. 3b) . Consequently, several genes with 170 elevated expression in ZNF451-BAG2 neuroblastoma were strong indicators of shorter overall survival 171 e.g. ENOSF1 (exemplified in Fig. 3c ). In contrast, genes that are strong predictors of longer overall 172 survival showed decreased expression in ZNF451-BAG2 expressing neuroblastoma cases (exemplified 173 in Fig. 3d ). In addition, k-means analysis revealed that a subset of ZNF451-BAG2 associated transcripts 174 clustered the 498-SEQC cohort into two groups (Fig. 3e ). Group 1, with predominantly low expression 175 levels, consists mainly of low-risk tumors, with low stages according to INSS and lack of MYCN 176 amplification whereas the opposite is evident for group 2 wherein expression levels of ZNF451-BAG2 177 associated transcripts are high ( Fig. 3e ). Consequently, patients with group 2 tumors have a 178 significantly shorter overall survival ( Fig. 3f ). Gene set enrichment analysis (25) of transcriptional 179 differences between ZNF451-BAG2 expressing NB and those lacking ZNF451-BAG2 expression showed 180 a significant enrichment of cell cycle associated gene sets and a depletion of apoptosis related gene 181 set ( Fig. 3g-h) . 182
183
The ZNF451-BAG2 fusion generates a truncated BAG2 protein, present in a subset of neuroblastoma 184 tumors 185
The ZNF451-BAG2 fusion spans the 3' UTR or exon 14 of ZNF451 and the second exon of BAG2, 186 potentially generating a truncated BAG2 transcript lacking the first exon ( Fig. 4a ). Its first exon encodes 187 part of a coiled-coil domain that is absent in the ZNF451-BAG2 fusion (Fig. 4a ). Full length BAG2 188 encodes a 23.8 kDa protein, whereas the ZNF451-BAG2 fusion transcript encodes a smaller 19.6 kDa 189 protein (∆BAG2) (Fig. 4a ). The ZNF451-BAG2 chimera was present in 31 of the 172 sequenced tumors 190 (18%). Alignment of wild-type BAG2 protein (BAG2) across different species showed that in ∆BAG2 the 191 highly conserved N-terminal coiled-coil domain was truncated ( Supplementary Fig. 3a ), implying 192 functional relevance of the truncated region for BAG2. To understand if tumors wherein ZNF451-BAG2 193 was identified ( Fig. 2f ) also had detectable levels of ∆BAG2 protein, we performed immunoblotting 194 with an antibody targeting BAG2. All probed (n=13) tumors contained BAG2 protein at varying levels 195 however only five tumors also co-expressed detectable levels of ∆BAG2, while no detectable levels of 196 ∆BAG2 were observed in tissue from six human normal adrenal glands ( Fig. 4b and Supplementary Fig.  197 3b). 198 199 ∆BAG2 impairs clearance of phosphorylated TAU and binding to HSC70
200
BAG2 has been shown to be important for clearance of phosphorylated forms of the TAU protein 201 (pTAU) and thus been implicated as a stabilizer of microtubules (23). To test if this capacity was 202 attenuated by the presence of ∆BAG2 we probed the levels of pTAU in a panel of neuroblastoma 203 tumors and normal adrenal glands. This showed a clear association between the presence of pTAU and 204 endogenous ∆BAG2 ( Fig. 4b and Supplementary Fig. 3b ). To validate that this was caused by ∆BAG2 205 protein expression, we cloned and validated the ∆BAG2 transcript where after we expressed it and 206 BAG2 alone or in combination in SK-N-FI neuroblastoma cells. Upon BAG2 overexpression, the levels 207 of pTAU were significantly reduced whereas total TAU was present in amounts similar to those in 208 control-transduced cells (Fig. 4c ). ∆BAG2 overexpressing cells retained pTAU levels and more 209 importantly, upon co-expression BAG2 failed to clear pTAU ( Fig. 4Cc ), implying that ∆BAG2 can act as 210 a negative regulator of BAG2 function. BAG2 has been shown to bind the heat shock cognate 70 211 (HSC70) (26), a chaperone protein important for pTAU ubiquitination (27) and axon outgrowth (28). 212
Overexpression of BAG2 and ∆BAG2 in SK-N-FI neuroblastoma cells followed by BAG2 213 immunoprecipitation via FLAG revealed that BAG2 but not ∆BAG2 binds a 70 kDa protein 214 ( Supplementary Fig. 3c ). Since BAG2 has been reported to bind HSC70 (26), we performed additional 215 immunoprecipitation followed by immunoblotting with a HSC70 specific antibody. This revealed that 216 BAG2 binds HSC70, whereas ∆BAG2 does not (Fig. 4d) . 217
218
∆BAG2 impedes differentiation of neuroblastoma in response to retinoic acid
219
To investigate whether ∆BAG2 impinges on the capacity of neuroblastoma cells to differentiate, we 220 treated CTRL (empty vector), BAG2 or ∆BAG2 expressing SK-N-FI cells (Fig. 4E ) with retinoic acid (RA), 221 a compound used in adjuvant therapy of high-risk neuroblastoma patients (13). After six days of RA 222 treatment, cells transduced with either CTRL (Fig. 4f-g, l) or BAG2 (Fig. 4h -i, l) acquired neuronal 223 morphology with long neurites. In contrast, ∆BAG2 transduced cells exhibited a weaker response to 224 RA, with significantly less neurite formation ( Fig. 4j-l) . To validate this effect we transduced SK-N-BE(1) 225 neuroblastoma cells with a doxycycline-inducible version of the ∆BAG2 fusion genes (Fig. 4m ). Upon 226 doxycycline induction, ∆BAG2 expressing cells exhibited a reduced capacity to respond to RA ( Fig. 4n-227 r). 228 229
Alternative splicing affects the generation of neuroblastoma specific fusions 230
Previously it has been suggested that cis-splicing between adjacent genes can generate fusion 231 transcripts in prostate cancer (5, 6). To elucidate whether there was a correlation between distance 232 and frequency we plotted the distance between 5' and 3' of the fusion junction in the 233 intrachromosomal fusion transcript versus the fusion frequency in the NB172 and NB-v data sets (Fig.  234 5a). Fusions occurring at high frequency in both data sets were enriched between 1 to 100kb, whereas 235 transcripts separated by more than 100kb occurred at lower frequencies and almost exclusively in the 236 larger NB172 data set (Fig. 5a ). The spatial proximity of identified transcripts suggests that these 237 fusions are the result of cis-splicing (5, 8) . Inspection of nucleotide sequences located at 5' and 3' of 238 the fusion junctions for canonical splicing donors (GT) and acceptors (AG) revealed that 81.9% carried 239
GT and AG at the 5' and 3' fusion sites (GT*AG) (Fig. 5b) . Notably, 87% of intra-chromosomal fusions 240 had GT*AG at the fusion junction whereas only 45.9% of inter-chromosomal fusions contained 241 canonical splice sites at the junctions. This pattern was unique to neuroblastoma as fusions detected 242 in normal adrenal gland, osteosarcoma and rhabdoid tumor exhibited no enrichment of splice sites 243 ( Fig. 5b ). Aberrant RNA splicing has been suggested as a driving event for several cancers and 244 mutations in genes coding for components of the spliceosome have been identified in several tumors 245 (29) . Furthermore in breast cancer, it has been shown that an intact spliceosome is required to tolerate 246 oncogenic MYC hyperactivation (30). We compared expression levels of genes of the KEGG, 247 "Spliceosome" gene category between neuroblastoma and normal adrenal gland. Out of 134 genes 46 248 had significantly higher expression levels in the neuroblastoma, whereas only three had lower levels 249 of expression ( Fig. 5c ). To further elucidate whether there were clinically relevant differences in 250 expression of spliceosome genes between low-and high-risk neuroblastoma we performed k-means 251 analysis of the 498-SEQC neuroblastoma cohort. Together with previous observations (31) our analysis 252 elucidates how the differential expression of spliceosome factors clearly identifies tumors of different 253 clinical outcome, with high expression levels of splicing factors predicting high-risk tumors with bleak 254 clinical outcome and substantially shorter overall survival ( Fig. 6d-e ). Furthermore, previous genome 255 sequencing studies of neuroblastoma patients revealed mutations in several spliceosome factors in 256 primary tumors and de novo mutations in spliceosome factors occurred in relapsed tumors (1, 2, 32, 257 33) (summarized in Supplementary Table 13 ). To investigate whether inhibition of spliceosome activity 258 would selectively impede the generation of fusion transcripts but not their wild type cognates, we 259 treated neuroblastoma cells (LAN-1 and SK-N-BE(1)) with the spliceosome inhibitor pladienolide B (34). 260 Upon treatment, there was a loss of expression for a majority of selected high frequency fusion 261 transcripts whereas expression of most wild type genes constituting the fusions were unaffected at 262 these concentrations (Fig 6a-b and Supplementary Fig. S4 ). To elucidate if selective loss of fusion 263 transcripts upon spliceosome inhibition was associated with increased apoptosis we treated the 264 neuroblastoma cell lines LAN-1 and SK-N-BE(1) with increasing concentrations of pladienolide B. As 265 controls we utilized non-transformed human diploid fibroblasts (HNDF). Already at 5nM the 266 neuroblastoma cell lines exhibited increased levels of cleaved caspase-3 and cleaved PARP, whereas 267 control cells showed no signs of cell death. At 20nM cell death in both neuroblastoma cell lines was 268 further increased but control cells were still non-responsive ( Fig. 6c ). 269
270 Discussion 271
Our study shows that a high frequency of neuroblastoma specific fusion transcripts could constitute 272 an overlooked process through which altered transcripts are generated. It has been shown that upon 273 cellular stress (e.g. viral infection, replicative or osmotic stress and mutational events) transcriptional 274 termination can be blocked, increasing the probability of generating "downstream of genes"-275 transcripts (11). Thus, a proportion of fusions could represent passengers that occur as a response to 276 cellular stress combined with neuroblastoma associated events such as gain or loss of chromosomal 277 regions (e.g. 17q and 2p). In contrast to such passengers, certain fusions could be early events actually 278 preceding and promoting other transformative events. Pharmacologic inhibition of splicing selectively 279 repressed expression of several top frequent fusion transcripts but not of their wild-type cognates and 280 there was a high frequency of splicing donor/acceptor sites in neuroblastoma specific fusions but not 281 in fusions detected in normal adrenal gland, osteosarcoma or rhabdoid tumors. This pattern implies 282 that a substantial proportion of the detected fusions are of the same cis-splicing type as previously 283 reported in prostate cancer (5). Our analysis reveals that high expression levels of splicing associated 284 factors is a distinguishing feature of high-risk neuroblastoma, representing a strong predictor of tumor 285 grade. Regardless of the mechanisms underlying the generation of these fusions, they are not 286 necessarily dependent on amino acid changing mutations but can still provide a source of modified 287 gene products with the potential to promote neuroblastoma but also reveal novel drug targets. Given 288 the low frequency of recurrent mutations in neuroblastoma, such a pool of altered gene products could 289 indeed be relevant for tumor pathophysiology. A background of expressed fusion transcripts 290 potentially augments the effect of oncogenic drivers. Interestingly, our analysis shows that when 291 established drivers of neuroblastoma (e. g. MYCN and LMO1) are part of the fusion transcripts the 292 expression levels of wild type cognates are elevated. In addition, a panel of neuroblastoma specific 293 fusions occurring at high frequency could serve as biomarkers for diagnosis and the presence of risk 294 specific fusions could sub-divide neuroblastoma patients for precision therapy. Hence, fusions that are 295 passenger events rather than oncogenic drivers can still be of clinical relevance. One concern with 296 previously reported fusions is the relatively few cases that have been independently validated. In 2015, 297 only 3% of fusions identified by deep sequencing could be reproducibly detected (4). Arguably, the 298 "non-genomic" characteristic of this type of intrachromosomal fusions potentially augments the 299 detection of false positives. The risk that a proportion of fusion transcripts constitute false positives as 300 the result of spurious transcription or of sequencing errors is reduced by our crosswise analysis with 301 other tumors and healthy tissues. There is a clear enrichment of common fusions unique for the 302 neuroblastoma data sets that do not appear in any of the other tumors nor in normal adrenal glands. 303
It should however be noted that the normal adrenal gland is not perfect as control tissue due to the 304 cellular heterogeneity of the organ. Nevertheless, neuroblastoma specific fusions are enriched for 305 genes located at chromosomal regions (2p or 17q) which are commonly gained in high-risk 306 neuroblastoma. The selective loss of several fusion transcripts upon spliceosome inhibition is an 307 additional strong indication that fusion transcripts indeed are present. Our validation of ten fusions 308 through PCR and subsequent sequencing further underscores that these fusions can generate 309 alternative gene products. Interestingly, tumor specific distribution of fusions is reflected in the 310 osteosarcoma tumors where the TP53 tumor suppressor is a fusion partner in an disproportional 311 amount of the detected fusions, mirroring the importance of inactivating mutations in TP53 for this 312 disease (22) . It has previously been reported that the presence of short homology sequences (SHS) 313 can generate false RNA-chimeras due to template switching during the reverse transcriptase reaction 314 (35). Such a mechanism would presumably generate random fusions between transcripts containing 315 matching SHSs with no preference for any particular chromosomal location nor any preference for 316 intrachromosomal vs interchromosomal fusion transcripts. The non-random enrichment of fusions at 317 chromosomal locations that mirror the disease as well as the enrichment of intrachromosomal fusions 318 between closely located genes suggests that reverse transcriptase induced template switching is not 319 the cause of these fusions. Furthermore, it is plausible that fusions detected due to random template 320 switching should correlate with high expression levels, which we do not detect. Our study shows that 321 an altered protein with novel properties can be generated as a consequence of an intrachromosomal, 322 splicing dependent fusion and that this altered protein influences the response to a drug (RA) 323 commonly used to treat high-risk neuroblastoma patients. However, to fully evaluate the importance 324 of identified fusions further functional experiments are required. A previous study indeed shows how 325 the SLC45A3-ELK4 read-through fusion transcript is elevated in prostate cancer tissue, is androgen-326 regulated and can be detected in an non-invasive assay from biopsies of men at risk of having prostate 327 cancer (9). Even though it is possible that a portion of individual fusions are passenger events rather 328 than oncogenic drivers a continued effort is justified to understand the regulation of fusions and 329 (14) was applied to detect the fusion transcripts in paired-end RNA-seq 349 data. Reads were mapped to hg19 and differential expression analysis was performed as described 350 in(37). For enrichment analysis in Figure 1c , only fusions occurring above ~3% in each risk group were 351 included (1 case in Low/Intermediate-risk, 4 cases in High-risk and 5 cases for the common fusion 352 transcripts shared by Low/Intermediate-risk and high-risk groups). 353
354
Cloning and expression of wildtype BAG2 and ZNF451-BAG2. cDNA was synthesized from total RNA 355 by the iScript cDNA Synthesis Kit (Bio-Rad). Coding regions of wildtype BAG2 and ZNF451-BAG2 were 356 amplified from SK-N-AS cells for subcloning into p3XFLAG-CMV14 (Sigma) and pLVX-EF1α-IRES-357 mCherry (Clontech) using primer pair 1 and 2 respectively ( Supplementary Table 11 ), inserted to pCR-358 Blunt II-TOPO vector via zero Blunt TOPO PCR Cloning Kit (ThermoFisher Scientific) and sequenced. 359
BAG2 and ZNF451-BAG2 were subcloned into p3XFLAG-CMV14 vector using EcoRI and BamHI and 360 pLVX-EF1α-IRES-mCherry lentiviral vector using EcoRI and BamHI. To generate pLVX-Tetone-puro-361 IRES-mCherry-empty/BAG2/ZNF451-BAG2 vectors, pLVX-Tetone-puro-empty (Clontech) construct was 362 linearized with AgeI, blunted and digested with EcoRI; pLVX-EF1α-IRES-mCherry-363 empty/BAG2/ZNF451-BAG2 vectors were linearized with MluI, blunted and digested with EcoRI to 364 release IRES-mCherry-empty/BAG2/ZNF451-BAG2; then linearized and blunted pLVX-Tetone-puro-365 empty construct was ligated with fragment of IRES-mCherry-empty/BAG2/ZNF451-BAG2 separately. 366
Lentiviruses expressing pLVX-EF1α-IRES-mCherry-empty/BAG2/ZNF451-BAG2 and pLVX-Tetone-puro-367 IRES-mCherry-empty/BAG2/ZNF451-BAG2 were produced in 293FT cells using lipofectamine 2000 368 based protocol. 369 370 Cell culture. All neuroblastoma cell lines (SH-SY5Y, SK-N-SH, SK-N-FI, SK-N-BE(1), SK-N-AS, LAN-1, CHP-371 212 and IMR-5) were maintained in RPMI1640 medium supplemented with 10% FBS, 1% 372 penicillin/streptomycin and 1% L-glutamine and grown in 5%CO2 at 37°C. 373 374 Differentiation assay and immunofluorescence staining. For short-term RA induced differentiation 375 assay, SK-N-FI cells were seeded in 6 well plates; after 24 hours, cells were infected by lentiviruses 376 expressing pLVX-EF1α-IRES-mCherry-empty/BAG2/ZNF451-BAG2 for 48 hours; then cells were 377 trypsinized and 20,000 cells were reseeded into 6 well plates with coverslips; 24h later, cells were 378 treated with 1 µM retinoic acid (RA) or DMSO as control for 6 days. For doxycycline-inducible system, 379 20,000 SK-N-BE(1) cells with stable overexpression of pLVX-Tetone-puro-IRES-mCherry-ZNF451-BAG2 380 were seeded in 6 well plates with coverslips, and after 24h, cells were pre-treated with 1 µM 381 doxycycline or DMSO as a control for one day; then cells received one of the following 4 different 382 treatment for 4 days: DMSO, 1 µM RA, 1 µM doxycycline or 1 µM RA+1 µM doxycycline. 383
Cells on coverslips were fixed in RPMI1640 medium containing 2% PFA for 5 minutes at room 384 temperature (RT), washed once with PBS at RT, fixed with 4% PFA for another 15 minutes at RT and 385 washed twice with cold PBS; then cells were permeabilized with PBS containing 0.25% Triton X-100 for 386 15 minutes at RT and blocked with 3% BSA for 1h at RT. Immunofluorescent stainings were performed 387 with the following primary antibody Tuj1 (Covance, 1:1000) overnight at +4 °C. 388 389 Quantification. Cells were stained as in Fig. 4g-l and o-r. Images were taken by confocal microscopy 390 (10X). For quantification, images were coded and a researcher who had not participated in staining 391 and image acquisition manually counted the ratio of transduced cells extending TUJ1 + neurites/total 392 number of transduced cells/microscopic field. For DOX -SK-N-BE(1) the ratio of cells extending TUJ1 + 393 neurites/total number of cells/microscopic field were counted. Microscopic fields containing less than 394 three transduced cells were discarded. Grubb´s test was performed for outlier detection (alpha 395 p<0.05). For statistical analysis in Fig. 4l and r Transfection of p3XFLAG-CMV14-empty/BAG2/ZNF451-BAG2 constructs was performed using 406 lipofectamine 2000. 48 hours post-transfection, cells were harvested and proteins were extracted 407 using lysis buffer containing 10 mM TRIS-HCl (pH7.4), 150 mM NaCl, 0.5% NP40, complete protease 408 and phosphatase inhibitors (Roche). FLAG-tagged fusion proteins were immunoprecipitated using 409 Anti-FLAG M2 magnetic beads (Sigma) according to manufacturer's instructions. Bound proteins were 410 examined by silver staining or Western blotting using standard protocols. 411 412 
Figure legends

